Table 2

Neutralizing antibody titers of mice injected once with the vaccine and virus titers in the lungs after challenge
Vaccine NT titer to Virus titer in lungs, mean log PFU/g ±Sea
Strain Protein, μg Formulation Narita/09 Sw/Hok/81
PBS - - <10, <10, <10, <10, <10 <10, <10, <10, <10, <10 5.0±0.17
Narita/09 4 ES <10, <10, <10, <10, <10 ND 4.6±0.10
20 ES <10, 20, 20, 20, 40 ND 4.6±0.12
100 ES 20, 40, 80, 160, 160 ND 4.1±0.35
Narita/09 4 WV 40, 40, 40, 80, 160 ND 4.2±0.17
20 WV 40, 80, 160, 160, 320 ND 3.9±0.25*
100 WV 320, 320, 640, 1280, 1280 ND 2.4±0.50**
Sw/Hok/81 4 ES <10, <10, <10, <10, <10 <10, <10, <10, 10, 10 4.6±0.04
20 ES <10, <10, <10, <10, <10 <10, 10, 10, 20, 80 4.4±0.02
100 ES <10, <10, <10, <10, <10 10, 20, 20, 40, 40 4.7±0.02
Sw/Hok/81 4 WV <10, <10, <10, <10, <10 20, 40, 40, 40, 80 4.5±0.06
20 WV <10, <10, <10, <10, <10 20, 40, 80, 80, 80 4.4±0.04
100 WV <10, <10, <10, <10, <10 160, 160, 160, 160, 320 4.3±0.09

Mice were injected with each vaccine subcutaneously. Serum samples were collected 3 weeks after injection.

The animals were challenged by intranasal administration of 106.0 PFU of A/Narita/09.

At 3 days after challenge, lungs samples were collected and virus titers were measured. ES: ether split vaccine, WV: whole inactivated vaccine

a: Data are for 5 mice.

*: P<0.05, vs. virus titers in PBS group.

**: P<0.01, vs. virus titers in PBS group.

Okamatsu et al.

Okamatsu et al. Virology Journal 2013 10:47   doi:10.1186/1743-422X-10-47

Open Data